The Investor
28 Apr 2026, 17:08
AstraZeneca announced that its inhaled therapy Breztri Aerosphere has been approved in the United States for the maintenance treatment of asthma in patients aged 12 and older.
The approval makes Breztri the first and only triple-combination inhaler therapy for asthma, expanding its use beyond COPD. Clinical trials showed significant improvements in lung function and rapid onset of action compared to dual therapies.
The decision addresses a major unmet need, as many asthma patients remain uncontrolled on existing treatments, and marks a key milestone in respiratory care innovation.
Source: AstraZeneca
The approval makes Breztri the first and only triple-combination inhaler therapy for asthma, expanding its use beyond COPD. Clinical trials showed significant improvements in lung function and rapid onset of action compared to dual therapies.
The decision addresses a major unmet need, as many asthma patients remain uncontrolled on existing treatments, and marks a key milestone in respiratory care innovation.
Source: AstraZeneca